Bedrijfsoverzicht
YD Bio Ltd is a biopharmaceutical entity headquartered in Taipei, Taiwan, dedicated to advancing blood-based cancer detection methodologies and developing stem cell- and exosome-based therapeutics aimed at transforming treatments for a spectrum of diseases with unmet medical needs. Operating within the Healthcare sector and specifically the Biotechnology industry, the company focuses on high-potential therapeutic areas that often require significant research and development before commercialization. The firm currently maintains a market capitalization of $441.46M, reflecting its position as a mid-to-large cap entity in the biotech landscape, while reporting annual revenue of $510,360 over the trailing twelve months. Although specific employee count data is unavailable, the valuation metrics suggest an organization that has secured substantial market interest despite the relatively modest revenue base, indicating a potential reliance on future product approvals or partnerships to drive long-term value.
Financiële gezondheid
The company reported revenue of $510,360 for the trailing twelve months, yet posted a net income of $-1,411,559, revealing a significant gap where operating expenses and research costs far exceed current revenue generation. This structural deficit is further highlighted by an EBITDA of $-1,357,195, which underscores the heavy investment in R&D and operational overhead typical of early-stage biotechnology firms. Free cash flow stands at $-3,875,569, indicating that the company is burning through cash reserves to fund its operations and development pipeline rather than generating immediate liquidity from core business activities. Margin analysis shows a gross margin of 30.4%, suggesting that cost of goods sold is managed efficiently relative to sales, while the operating margin sits at -444.6% and the profit margin at -276.6%, both of which reflect the intense cost pressures inherent in the current business model. The balance sheet presents a mix of constraints and resources, with cash holdings of $3.13M against total debt of $22,265, resulting in a debt-to-equity ratio of 0.34 that suggests a relatively conservative leverage profile for a company in such a volatile sector. Liquidity is supported by a current ratio of 13.18, which indicates a very strong ability to meet short-term obligations with current assets. However, the return on equity is -42.7% and the return on assets is -25.4%, metrics that reveal management is currently unable to generate positive returns on capital deployed, a common challenge for biotech firms awaiting regulatory milestones.
Waarderingsbeoordeling
The P/E Ratio (TTM) and Forward P/E are both listed as N/A due to the negative earnings, meaning traditional valuation multiples based on profitability cannot be applied to assess the current stock price directly. Consequently, the market capitalizes the company at a Price to Book ratio of 1.37, indicating that investors are valuing the firm at a 37% premium over its net book value, likely anticipating future growth from its drug pipeline. Alternative valuation metrics provide further insight, with a Price to Sales ratio of 865.00 and an EV/EBITDA of -4.36, suggesting that the market is pricing the stock primarily on its asset base and potential rather than current earnings power or sales efficiency. Price volatility is contextualized by a 52-Week High of $25.00 and a 52-Week Low of $5.30, placing the current trading price significantly below the recent peak and implying a potential pullback from the high valuation extremes seen earlier in the year. The stock exhibits a Beta of 0.22, which indicates that the share price is considerably less volatile than the broader market, offering a distinct risk profile compared to typical high-beta biotechnology peers that often swing sharply with clinical trial results.
Growth & Income
Revenue growth demonstrates a robust YoY increase of 95.6%, signaling a rapid expansion in sales or a significant one-time revenue event, whereas earnings growth is N/A due to the negative net income, implying that top-line growth has not yet translated into profitability. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that all available cash flow is being retained and reinvested into research and development rather than distributed to shareholders. The disparity between the 95.6% revenue surge and the lack of earnings growth highlights the typical trajectory of a company scaling up operations before achieving commercial profitability. Overall, the financial profile presents a high-growth, zero-income opportunity where the primary value driver is the potential for the blood-based cancer detection and stem cell therapies to reach commercial viability.